Acoramidis Shows Consistent Benefit in Wild‑Type and Variant Transthyretin Amyloid Cardiomyopathy — Signal Extends Through 42 Months
Posted inCardiology news

Acoramidis Shows Consistent Benefit in Wild‑Type and Variant Transthyretin Amyloid Cardiomyopathy — Signal Extends Through 42 Months

In ATTRibute‑CM and its open‑label extension, acoramidis (712 mg twice daily) produced consistent reductions in all‑cause mortality and cardiovascular hospitalizations in both wild‑type and variant ATTR cardiomyopathy, including p.Val142Ile, with mortality benefit persisting through month 42.
Myocardial Infarction and Late-Onset Epilepsy: Unraveling Bidirectional Vascular Risks in Aging Populations
Posted inCardiology Clinical Updates Neurology news

Myocardial Infarction and Late-Onset Epilepsy: Unraveling Bidirectional Vascular Risks in Aging Populations

Emerging cohort evidence reveals myocardial infarction significantly elevates late-onset epilepsy risk, with late-onset epilepsy also predicting subsequent myocardial infarction and vascular mortality, underscoring shared systemic vascular pathology and implications for integrated vascular risk management.
Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings
Posted inCardiology Diabetes & Endocrinology news

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings

A retrospective MIMIC‑IV cohort presented at AHA 2025 found perioperative metformin exposure in T2DM patients undergoing cardiac surgery associated with markedly lower 30‑, 90‑ and 360‑day mortality. Results are compelling but observational—randomized trials are needed to confirm causality and define perioperative use.
RSV prefusion F bivalent vaccine protects older adults similarly whether or not they have atherosclerotic cardiovascular disease
Posted inCardiology news Respiratory

RSV prefusion F bivalent vaccine protects older adults similarly whether or not they have atherosclerotic cardiovascular disease

In a prespecified secondary analysis of the DAN‑RSV randomized trial, the bivalent RSV prefusion F vaccine showed comparable effectiveness against RSV‑related respiratory hospitalizations in adults ≥60 years with and without pre‑existing atherosclerotic cardiovascular disease (ASCVD); no clear reduction in major adverse cardiovascular events was observed.
Percutaneous Strategy (TAVI + FFR-guided PCI) Outperforms SAVR + CABG at 1 Year in Patients ≥70 with Severe Aortic Stenosis and Complex Coronary Disease: Results of the TCW Randomised Trial
Posted inCardiology news

Percutaneous Strategy (TAVI + FFR-guided PCI) Outperforms SAVR + CABG at 1 Year in Patients ≥70 with Severe Aortic Stenosis and Complex Coronary Disease: Results of the TCW Randomised Trial

The TCW trial randomized 172 patients ≥70 years with severe aortic stenosis and complex coronary disease to FFR-guided PCI plus TAVI versus SAVR plus CABG. At 1 year the percutaneous strategy met non-inferiority and demonstrated superiority for a composite endpoint driven by lower mortality and life‑threatening bleeding.